Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05190445
Title Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Pieris Pharmaceuticals, Inc.

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma


PRS-343 + Tucatinib

Paclitaxel + PRS-343 + Ramucirumab

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.